Brokers Set Expectations for NXL Q3 Earnings

Nexalin Technology, Inc. (NASDAQ:NXL) – Equities researchers at Maxim Group issued their Q3 2026 EPS estimates for Nexalin Technology in a research note issued to investors on Tuesday, September 29th. Maxim Group analyst A. Vendetti anticipates that the company will post earnings of ($2.70) per share for the quarter. The consensus estimate for Nexalin Technology’s current full-year earnings is ($11.40) per share. Maxim Group also issued estimates for Nexalin Technology’s Q4 2026 earnings at ($2.70) EPS, FY2026 earnings at ($11.40) EPS and FY2027 earnings at ($9.30) EPS.

Nexalin Technology (NASDAQ:NXL) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.00) by $2.89. Nexalin Technology had a negative net margin of 4,141.94% and a negative return on equity of 278.24%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.09 million.

A number of other equities research analysts also recently weighed in on NXL. Weiss Ratings downgraded Nexalin Technology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 25th. Zacks Research raised Nexalin Technology to a “hold” rating in a report on Thursday. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Nexalin Technology presently has a consensus rating of “Reduce”.

Nexalin Technology Stock Down 24.1%

NASDAQ NXL opened at $5.73 on Friday. Nexalin Technology has a twelve month low of $4.00 and a twelve month high of $60.00. The stock has a market cap of $4.18 million, a P/E ratio of -0.40 and a beta of 4.08. The company’s 50-day simple moving average is $7.63 and its 200 day simple moving average is $10.69.

Hedge Funds Weigh In On Nexalin Technology

A hedge fund recently bought a new stake in Nexalin Technology stock. PEAK6 LLC purchased a new stake in Nexalin Technology, Inc. (NASDAQ:NXL) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 476,509 shares of the company’s stock, valued at approximately $266,000. PEAK6 LLC owned approximately 2.56% of Nexalin Technology as of its most recent SEC filing. Institutional investors and hedge funds own 0.65% of the company’s stock.

Nexalin Technology News Roundup

Here are the key news stories impacting Nexalin Technology this week:

• Positive Sentiment: Nexalin signed an exclusive distribution and local manufacturing agreement for its ANVISA-approved Nexalin Sync™ neurostimulation device in Brazil and six other South American countries. The initial commercialization program covers 100 devices and a potential market of more than 300 million people, offering a possible path toward commercial revenue and larger government or private-sector contracts. Nexalin South America distribution and manufacturing agreement
• Positive Sentiment: Nexalin said it regained compliance with Nasdaq requirements on September 30. This removes an immediate listing threat, although the company remains exposed to further compliance and trading risks. Nexalin regains Nasdaq compliance
• Neutral Sentiment: Trading in NXL was repeatedly paused under Nasdaq’s Limit Up-Limit Down mechanism on October 1, indicating unusually sharp price movements and heightened speculative activity. The halts do not represent a change in the company’s fundamentals.
• Negative Sentiment: Maxim Group expects Nexalin to report a loss of $2.70 per share in both the third and fourth quarters of 2026, a full-year loss of $11.40 per share, and a $9.30 per-share loss in 2027. These forecasts reinforce concerns about near-term profitability, particularly given the company’s very small revenue base and historically negative margins. Maxim Group NXL earnings forecast

About Nexalin Technology

Nexalin Technology, Inc is a medical technology company focused on developing noninvasive neurostimulation devices designed to support brain health. Its technology uses cranial electrotherapy stimulation to deliver low-level electrical signals through electrodes placed on the head, with the aim of influencing brain activity without surgery or implanted hardware.

The company’s product portfolio includes the Nexalin Gen-2 and Gen-3 devices, which are designed for use in clinical and other supervised settings.